Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antacids Market

Antacids Market - By Drug Class (Proton Pump Inhibitors, Acid Neutralizers, Anti-H. Pyrolic Drugs), Indication (Gastroesophageal Reflux Disease, Heartburn, Gastritis), Dosage, Route of Administration, Distribution Channel – Global Forecast (2024 – 2032)

  • Report ID: GMI9703
  • Published Date: May 2024
  • Report Format: PDF

Antacids Market Size

Antacids market size was valued at around USD 7.1 billion in 2023 and is estimated to grow at 5.1% CAGR from 2024 to 2032. Antacids are medications used to neutralize stomach acid, providing relief from symptoms such as heartburn, indigestion, and acid reflux. These over-the-counter (OTC) drugs or prescription drugs work by reacting with gastric acid to form salts and water, thereby raising the pH level in the stomach and reducing acidity.

Antacids Market

The rising prevalence of gastrointestinal disorders such as peptic ulcers, gastritis, gastroesophageal reflux disease, serves as a significant driving factor for the market. For instance, according to the National Institutes of Health (NIH), the global prevalence of peptic ulcer disease surged from approximately 6,434,103 cases to 8,090,476 cases in 2019, globally. This underscores the pressing need for effective treatments and symptomatic relief, fueling the demand for antacid medications and driving growth in the market.

Furthermore, dietary and lifestyle changes, increased awareness and self-medication, and pharmaceutical advancements, are the promoting factors advancing the growth of the market.

Antacids Market Trends

In the dynamic realm of gastrointestinal health management, the integration of dietary and lifestyle modifications alongside the use of antacids emerges as a pivotal strategy for achieving comprehensive symptom relief and long-term wellness. As individuals increasingly seek holistic approaches to address digestive discomfort and optimize overall health, the synergy between dietary adjustments, lifestyle changes, and pharmacological interventions becomes ever more significant.

  • Dietary and lifestyle changes can complement the use of antacids by addressing underlying factors contributing to gastrointestinal symptoms. For example, avoiding trigger foods such as spicy or acidic items, reducing alcohol and caffeine consumption, and adopting healthier eating habits can help minimize the frequency and severity of symptoms.
  • Incorporating dietary and lifestyle changes can reduce the need for frequent or prolonged use of antacids, minimizing the risk of potential side effects associated with medication use. This can lead to cost savings for consumers and healthcare systems and promote overall well-being by emphasizing natural approaches to health management.
  • When combined with antacid therapy, dietary and lifestyle modifications can enhance the effectiveness of treatment. Avoiding large meals before bedtime can help prevent nocturnal reflux, while maintaining a healthy weight can reduce abdominal pressure and lower the risk of gastroesophageal reflux disease (GERD) symptoms, thereby increasing the growth of the market.

Antacids Market Analysis

Antacids Market, By Drug Class, 2021 – 2032 (USD Billion)

Based on drug class, the market is classified into proton pump inhibitors, acid neutralizers, anti-H.Pyrolic drugs, H2 antagonists, pro-motility agents, prostaglandin analogous, and other drug class. The proton pump inhibitors segment is estimated to account for USD 3.5 billion by 2032.

  • Proton pump inhibitors are highly effective at reducing stomach acid production by inhibiting the proton pump in the gastric parietal cells. This strong acid suppression provides relief from symptoms of acid reflux, gastroesophageal reflux disease (GERD), and peptic ulcers.
  • They typically provide longer-lasting relief compared to other antacid medications. They can effectively control acid production for up to 24 hours with once-daily dosing, offering convenience and improved adherence for patients.
  • Further, proton pump inhibitors are commonly prescribed to reduce the risk of developing ulcers in patients who require long-term use of nonsteroidal anti-inflammatory drugs, which is estimated to reach USD 233.6 billion by 2032, (NSAIDs), which can irritate the stomach lining and increase the risk of ulcer formation. Thus, driving the growth of the market.


Antacids Market, By Indication (2023)

Based on indication, the antacids market is divided into gastroesophageal reflux disease, heartburn, indigestion, gastritis, peptic ulcer disease and other indication. The gastroesophageal reflux disease segment accounted for USD 2.2 billion in 2023.

  • Antacids provide rapid relief from the uncomfortable symptoms of GERD such as heartburn, acid reflux, and regurgitation. This quick onset of action is particularly beneficial for individuals experiencing acute episodes of reflux, allowing them to alleviate discomfort promptly.
  • Many antacids are available over-the-counter, making them easily accessible for individuals seeking relief from mild to moderate GERD symptoms without the need for a prescription. This accessibility enhances patient convenience and empowers individuals to manage their condition proactively.
  • Moreover, antacids primarily work locally within the gastrointestinal tract to neutralize stomach acid, with minimal systemic absorption. This characteristic reduces the risk of systemic side effects and drug interactions compared to medications that are absorbed into the bloodstream, enhancing the safety profile of antacid therapy.

Based on dosage, the antacids market is classified into tablets, liquid, and other dosages. The tablets segment is estimated to account for USD 6.4 billion by 2032.

  • Tablets are a convenient dosage form for antacids, providing a standardized and easily measurable dose of medication. They can be taken orally with water, making them suitable for use in various settings, including at home, work, or while traveling.
  • They are compact and lightweight, making them highly portable compared to other dosage forms such as liquids or suspensions. This portability allows individuals to carry their antacid medication with them and take it as needed, providing on-the-go relief from gastrointestinal symptoms.
  • Further, tablets are easy to swallow, especially for individuals who may have difficulty with chewable or effervescent formulations. Their smooth, solid dosage form makes them suitable for patients of all ages, including children and older adults. Thus, driving the growth of the market.

Based on route of administration, the antacids market is segmented into oral and injectable. The oral segment held a market share of 81.8% in the year 2023.

  • Oral administration is one of the most convenient and widely accepted routes of drug delivery. Antacids administered orally can be easily swallowed with water, making them suitable for individuals of all ages, including children and older adults.
  • They offer flexibility in dosing, allowing patients to adjust their dosage based on their symptoms and individual needs. This flexibility is particularly advantageous for individuals experiencing variable or intermittent symptoms of acid reflux, as they can tailor their dosage to achieve optimal symptom relief.
  • Additionally, oral medications are typically well-tolerated and non-invasive, leading to higher levels of patient compliance compared to other routes of administration such as injections or suppositories. Patients are more likely to adhere to their treatment regimens when medications can be taken orally, enhancing the effectiveness of therapy. Thus, stimulating the growth of the market.

Based on distribution channel, the antacids market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment accounted for USD 2.2 billion in 2023.

  • Hospital pharmacies typically stock a variety of antacid formulations to meet the diverse needs of patients, including tablets, liquids, suspensions, and intravenous (IV) preparations. This extensive formulary allows pharmacists to tailor treatment regimens to individual patient preferences, tolerances, and clinical presentations.
  • Hospital pharmacists are trained healthcare professionals with expertise in medication management and patient care. They can provide valuable insights into the selection, dosing, and monitoring of antacids, ensuring optimal therapy outcomes for patients with gastrointestinal disorders.
  • They are equipped to handle acute exacerbations of gastrointestinal symptoms requiring urgent treatment such as severe acid reflux or peptic ulcer bleeding. They ensure timely access to antacids and other medications, contributing to the efficient management of emergent situations in the hospital setting, thereby escalating the growth of the market.


North America Antacids Market, 2021- 2032 (USD Billion)

The U.S. antacids market is anticipated to grow at CAGR of 4.8% during the analysis timeframe.

  • The U.S. boasts a well-developed healthcare infrastructure with access to a wide range of medical services and products, including antacids. Patients have relatively easy access to healthcare facilities, pharmacies, and over-the-counter medications, facilitating the purchase and use of antacids.
  • The country has a sizable population with a high prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. This large consumer base drives demand for antacid products, contributing to the growth of the market.

Germany antacids market is anticipated to witness lucrative growth between 2024 – 2032.

  • Germany is home to a robust pharmaceutical industry, with leading companies specializing in drug development, manufacturing, and distribution. This industry expertise contributes to the availability of a wide range of high-quality antacid products in the market, including innovative formulations and delivery systems.

Japan antacids market is expected to grow significantly over the years.

  • Japan has stringent regulatory standards overseen by agencies such as the Pharmaceuticals and Medical Devices Agency (PMDA). These standards ensure the safety, efficacy, and quality of antacid products available in the market, instilling confidence in both healthcare professionals and consumers.
  • Japan is known for its advancements in healthcare technology and pharmaceutical research. Japanese companies invest heavily in research and development to develop innovative antacid formulations, delivery systems, and treatment approaches.

Saudi Arabia antacids market is anticipated to witness lucrative growth between 2024 – 2032.

  • Saudi Arabia has been investing significantly in developing its healthcare infrastructure, including hospitals, clinics, and pharmacies, to meet the growing healthcare needs of its population. This expanding infrastructure provides increased access to healthcare services and medications, including antacids.
  • There is a growing awareness among the Saudi population about gastrointestinal health issues and the importance of seeking medical treatment for symptoms such as heartburn, acid reflux, and indigestion. This increased awareness drives individuals to seek antacid medications for relief, contributing to market growth.

Antacids Market Share

The antacids industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive storage and analysis with improved efficiency and affordability. This includes advancements in processing, precision, automation, and customization. Competition is driven by factors such as the quality, reliability, and ease of usage along with integration capabilities with existing technologies, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.

Antacids Market Companies

Some of the eminent market participants operating in the antacids industry include:

  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gsk plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • The Procter & Gamble Company
  • Viatris Inc.

Antacids Industry News:

  • In May 2023, Lupin Limited completed the acquisition of Medisol, a French pharmaceutical company. This strategic move expanded Lupin's global presence and enhanced its portfolio by integrating Medisol's products and expertise. The acquisition provided Lupin with access to new markets, strengthened its research and development capabilities, and diversified its product offerings, ultimately contributing to the company's growth and competitiveness in the pharmaceutical industry.

The antacids market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

  • Proton pump inhibitors
  • Acid neutralizers
  • Anti-H.pyrolic drugs
  • H2 antagonists
  • Pro-motility agents
  • Prostaglandin analogous
  • Other drug classes

Market, By Indication

  • Gastroesophageal reflux disease
  • Heartburn
  • Indigestion
  • Gastritis
  • Peptic ulcer disease
  • Other indications

Market, By Dosage

  • Tablets
  • Liquid
  • Other dosages

Market, By Route of Administration

  • Oral
  • Injectable

Market, By Distribution Channel

  • Hospital pharmacy
  • Online pharmacy
  • Retail pharmacy

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global antacids industry size was valued at USD 7.1 billion in 2023 and is estimated to grow at 5.1% CAGR from 2024 to 2032 due to rising prevalence of gastrointestinal disorders and increasing pharmaceutical advancements.

The tablets segment of the market is forecasted to reach USD 6.4 billion by 2032 as they are compact and lightweight, easy to swallow, and convenient dosage form for antacids, providing a standardized and easily measurable dose of medication.

The hospital pharmacy segment of the market accounted for USD 2.2 billion in 2023 as they provide tailored antacid treatments and urgent care for gastrointestinal issues, enhancing patient outcomes and driving market growth through specialized medication management.

Aurobindo Pharma Limited, Bayer AG, Bristol Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gsk plc, Hikma Pharmaceuticals PLC, and Lupin Limited, among others.

Antacids Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 353
  • Countries covered: 23
  • Pages: 281
 Download Free Sample